在手术切除的食道状细胞癌中,对新辅助化学免疫疗法的单细胞反应概况
Gang Ji1, Qi Yang2, Song Wang3
1Department of Digestive Surgery, Xijing Hospital, Air Force Medical University, No. 169 Changle West Road, Xi'an, 710032, China.
Genome medicine
|April 2, 2024
概括
在食道状细胞癌 (ESCC) 中,新辅助化学免疫疗法 (NAT) 反应与癌细胞分化相关. 不那么差异化的瘤显示出更好的反应,而更差异化的瘤可能会抵抗NAT. 免疫细胞的特征也可以预测治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 食道状细胞癌 (ESCC) 治疗疗效是复杂的,因为瘤微环境 (TME).
- 在新辅助化疗-免疫疗法 (NAT) 期间了解ESCC的免疫环境对于优化患者策略至关重要.
研究的目的:
- 调查免疫格局与ESCC中NAT的病理反应之间的关联.
- 确定潜在的生物标志物和治疗点,以改善ESCC患者的NAT疗效.
主要方法:
- 从II/III阶段ESCC患者的22个基线和24个后NAT样本的单细胞分析.
- 对新辅助抗PD-1联合治疗的病理反应 (pCR,MPR,IPR) 的分析.
- 轨迹分析,转录组解卷和细胞间通信分析.
主要成果:
- 不那么差异化的ESCC瘤对NAT呈现出良好的病理反应,而更差异化的瘤则表现出耐药性.
- 特定的免疫细胞特征,包括CD8+效应T细胞和自然杀手细胞,与更好的病理反应有关,与IFNγ信号传递有关.
- 在响应者中观察到调节性T细胞和特定免疫检查点相互作用 (CTLA4-CD86,TIGIT-PVR) 的减少,这表明潜在的治疗点.
结论:
- 癌细胞分化是影响食道癌中对NAT的病理反应的重要因素.
- 该研究描绘了ESCC对NAT的反应免疫格局,提供了对治疗机制的见解.
- 针对接受NAT的ESCC患者,可以根据免疫细胞相互作用和癌细胞状态确定新的治疗点.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
05:57Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues
Published on: May 30, 2025
117
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
